PE20150356A1 - Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue - Google Patents
Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengueInfo
- Publication number
- PE20150356A1 PE20150356A1 PE2015000070A PE2015000070A PE20150356A1 PE 20150356 A1 PE20150356 A1 PE 20150356A1 PE 2015000070 A PE2015000070 A PE 2015000070A PE 2015000070 A PE2015000070 A PE 2015000070A PE 20150356 A1 PE20150356 A1 PE 20150356A1
- Authority
- PE
- Peru
- Prior art keywords
- dengue
- dengue virus
- vaccine compositions
- against infection
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion se refiere a composiciones de vacuna que son utiles en un metodo para proteger un sujeto humano contra la enfermedad del dengue. Una composicion de vacuna del virus del dengue serotipo 2 que comprende: (i) un antigeno contra el dengue seleccionado entre el grupo que consiste de: (a) un virus del dengue vivo atenuado, (b) un virus del dengue inactivo, (c) un virus del dengue vivo atenuado quimerico atenuado o inactivo, (d) una particula analoga al virus del dengue (VLP), y (e) una combinacion de dos o mas de (a) a (d), o bien, (ii) una construccion de acido o vector virico que puede expresar en una celula humana un antigeno del dengue que es una VLP del dengue, donde dicho antigeno del dengue comprende un polipeptido que tiene al menos una identidad del 90% con la SEC ID N�:12
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305908 | 2012-07-24 | ||
EP12305911 | 2012-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20150356A1 true PE20150356A1 (es) | 2015-03-20 |
Family
ID=48856641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015000070A PE20150356A1 (es) | 2012-07-24 | 2013-07-24 | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue |
Country Status (15)
Country | Link |
---|---|
US (1) | US20150265695A1 (es) |
EP (1) | EP2877207A1 (es) |
JP (1) | JP2015524422A (es) |
KR (1) | KR20150036593A (es) |
CN (1) | CN104812408A (es) |
AU (1) | AU2013295016A1 (es) |
BR (1) | BR112015001313A2 (es) |
CA (1) | CA2878599A1 (es) |
GT (1) | GT201500005A (es) |
HK (1) | HK1212905A1 (es) |
MX (1) | MX2015000446A (es) |
PE (1) | PE20150356A1 (es) |
PH (1) | PH12014502875A1 (es) |
SG (1) | SG11201500439RA (es) |
WO (1) | WO2014016362A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3177572A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
AU2014281713A1 (en) | 2013-06-21 | 2015-11-12 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
TW201620546A (zh) * | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
AU2015313650B2 (en) * | 2014-09-11 | 2021-07-08 | Vlp Therapeutics, Inc. | Flavivirus virus like particle |
CN106999568A (zh) * | 2014-12-22 | 2017-08-01 | 默沙东公司 | 登革病毒疫苗组合物及其使用方法 |
WO2017005652A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
EP3331559A4 (en) | 2015-08-03 | 2019-03-06 | The United States of America as represented by the Secretary of the Army, Walter Reed Army Institute Of Research (WRAIR) | PROTEIN OF RECOMBINANT DENGUE ENHANCING IMMUNITY |
PT3355915T (pt) * | 2015-09-29 | 2023-12-19 | Boehringer Ingelheim Animal Health Usa Inc | Vacinas de partículas pseudovirais (vlp) de parvovírus canino (cpv) e suas utilizações |
US11531029B2 (en) | 2017-05-08 | 2022-12-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and compositions for the detection of flavivirus infections |
WO2019069130A1 (en) | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE |
US11576962B2 (en) | 2017-12-21 | 2023-02-14 | Green Biomed, Inc. | Cross-immunizing antigen vaccine and method for preparation thereof |
DK3620174T3 (da) | 2018-09-05 | 2022-03-14 | Takeda Vaccines Inc | Enhedsdosis af dengue-vaccine og indgivelse deraf |
US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
DE69830579T2 (de) | 1997-02-28 | 2006-05-04 | Acambis, Inc., Cambridge | Chimäre impfstoffe gegen flaviviren |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
AU4179200A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
AU4040200A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
JP2002540166A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱3型ウイルスワクチン |
US6537557B1 (en) | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
AU6514900A (en) * | 1999-08-02 | 2001-02-19 | Wyeth | Rescue of mumps virus from cdna |
ES2374131T3 (es) | 2000-02-16 | 2012-02-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Flavivirus quiméricos avirulentos e inmunógenos. |
ATE412738T1 (de) | 2000-05-30 | 2008-11-15 | Univ Mahidol | Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen |
AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
EP1545572A4 (en) | 2001-05-23 | 2006-04-12 | Dendreon Corp | CELL SURFACE PROTEINS ACTIVATED CONJUGATES AND THERAPEUTIC USES THEREOF |
ES2439724T3 (es) | 2001-06-01 | 2014-01-24 | Sanofi Pasteur Biologics, Llc | Vectores de flavivirus quiméricos |
WO2003010197A2 (en) | 2001-07-25 | 2003-02-06 | Genset S.A. | Gmg-1 polynucleotides and polypeptides and uses thereof |
TR201806655T4 (tr) * | 2002-05-03 | 2018-06-21 | The Government Of The Secretary Department Of Health And Human Services | Dang tipi 4 genomunun 3' translate edilmemiş bölgesinin bir kesitinde bir 30 nükleotit delesyonunu (delta30) içeren bir rden3/4delta 30(me), rden2/4delta30(me) ya da rden1/4delta30(me) rekombinant kimerik dang virüsü olup, burada adı geçen 30 nükleotit delesyonu tl2 stem-loop yapısına karşılık gelir. |
WO2003101397A2 (en) | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
AU2004274937B9 (en) * | 2003-09-17 | 2011-04-14 | Duke University | Consensus/ancestral immunogens |
WO2006134443A1 (en) * | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
WO2006134433A1 (en) * | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
AU2006280144B2 (en) | 2005-08-10 | 2012-06-14 | Sanofi Pasteur Biologics, Llc | Vaccination against dengue virus infection |
CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
EP2117589A4 (en) * | 2007-01-31 | 2010-07-21 | Sanofi Pasteur Biologics Co | FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS |
BRPI0913012B1 (pt) * | 2008-04-30 | 2021-12-14 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Quimera de ácido nucleico, métodos para detectar um anticorpo do vírus da dengue em uma amostra de um paciente, e para produzir partículas virais que expressam proteínas prm e e do vírus da dengue, uso de vírus codificado pela quimera e flavivírus ou partícula viral quiméricos |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
AU2010277222A1 (en) * | 2009-07-29 | 2012-03-08 | Bryce Malcolm Buddle | Polymer particles and uses thereof |
US8900596B2 (en) * | 2009-11-18 | 2014-12-02 | The Board Of Regents Of The University Of Texas System | Physicochemical (PCP) based consensus sequences and uses thereof |
GB201007531D0 (en) | 2010-05-05 | 2010-06-23 | Imp Innovations Ltd | Composition |
US8993744B2 (en) * | 2010-05-21 | 2015-03-31 | University of Pittsburgh—of the Commonwealth System of Higher Education | Universal dengue virus sequences and methods of use |
WO2012051491A1 (en) * | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
EP3932422A1 (en) * | 2012-07-24 | 2022-01-05 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
-
2013
- 2013-07-24 JP JP2015523550A patent/JP2015524422A/ja active Pending
- 2013-07-24 PE PE2015000070A patent/PE20150356A1/es not_active Application Discontinuation
- 2013-07-24 AU AU2013295016A patent/AU2013295016A1/en not_active Abandoned
- 2013-07-24 EP EP13740025.5A patent/EP2877207A1/en not_active Withdrawn
- 2013-07-24 US US14/416,492 patent/US20150265695A1/en not_active Abandoned
- 2013-07-24 KR KR20157003822A patent/KR20150036593A/ko not_active Application Discontinuation
- 2013-07-24 CN CN201380049741.2A patent/CN104812408A/zh active Pending
- 2013-07-24 WO PCT/EP2013/065669 patent/WO2014016362A1/en active Application Filing
- 2013-07-24 SG SG11201500439RA patent/SG11201500439RA/en unknown
- 2013-07-24 CA CA2878599A patent/CA2878599A1/en not_active Abandoned
- 2013-07-24 BR BR112015001313A patent/BR112015001313A2/pt not_active IP Right Cessation
- 2013-07-24 MX MX2015000446A patent/MX2015000446A/es unknown
-
2014
- 2014-12-23 PH PH12014502875A patent/PH12014502875A1/en unknown
-
2015
- 2015-01-12 GT GT201500005A patent/GT201500005A/es unknown
-
2016
- 2016-01-28 HK HK16100914.5A patent/HK1212905A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150036593A (ko) | 2015-04-07 |
BR112015001313A2 (pt) | 2017-08-01 |
CN104812408A (zh) | 2015-07-29 |
CA2878599A1 (en) | 2014-01-30 |
EP2877207A1 (en) | 2015-06-03 |
MX2015000446A (es) | 2015-03-12 |
SG11201500439RA (en) | 2015-02-27 |
PH12014502875A1 (en) | 2015-02-23 |
HK1212905A1 (zh) | 2016-06-24 |
AU2013295016A1 (en) | 2015-01-29 |
WO2014016362A1 (en) | 2014-01-30 |
US20150265695A1 (en) | 2015-09-24 |
GT201500005A (es) | 2015-10-13 |
JP2015524422A (ja) | 2015-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20150356A1 (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
CY1119284T1 (el) | ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs) | |
AR090470A1 (es) | Vacuna contra el virus sincicial respiratorio (rsv) | |
MX2016004063A (es) | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. | |
AR080313A1 (es) | Composiciones de virus de moquillo canino (cdv) recombinante y sus usos | |
AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
BR112012033767A2 (pt) | processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina. | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
UY32457A (es) | Vacuna del virus del dengue inactivado | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
IN2012DN01577A (es) | ||
EA201500643A1 (ru) | Парвовирус свиней 5а, способы применения и вакцина | |
EA201991041A1 (ru) | Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения | |
WO2017156511A8 (en) | Live attenuated zika virus vaccine | |
JO3281B1 (ar) | مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي | |
MX2018015506A (es) | Vacuna contra virus de bronquitis infecciosa. | |
PH12015501721A1 (en) | Porcine parvovirus 5b, methods of use and vaccine | |
AR072976A1 (es) | Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo | |
CO6700818A2 (es) | Vectores de parapoxvirus | |
NI201700080A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas. | |
EA201500140A1 (ru) | Ослабленные вакцины от свиного гриппа и способы их получения и применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |